| Phase 13 trials |
|
Phase 1
|
NCT07170475 |
Jun 2025 → Mar 2026 overdue |
Parkinson disease |
Fujita Health University |
Recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT02614469 |
Mar 2015 → Apr 2016 |
— |
Michael Alan Schwarzschild |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT02288091 |
Jan 2015 → Mar 2016 |
amyotrophic lateral sclerosis |
Massachusetts General Hospital |
Completed
|
No outcome recorded
|
| Phase 24 trials |
|
Phase 2
|
NCT06355024 |
May 2024 → Jan 2025 |
triple-negative breast carcinoma |
Fudan University |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT03168711 |
Oct 2017 → Dec 2019 |
amyotrophic lateral sclerosis |
Massachusetts General Hospital |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT00833690 |
Jun 2009 → Dec 2012 |
Parkinson disease |
The Parkinson Study Group |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT00067327 |
Feb 2002 → Sep 2005 |
relapsing-remitting multiple sclerosis |
National Center for Complementary and Integrative Health (NCCIH) |
Completed
|
No outcome recorded
|
| Phase 2/31 trial |
|
Phase 2/3
|
NCT05809336 |
May 2019 → Oct 2022 |
neoplasm |
Beijing Friendship Hospital |
Completed
|
No outcome recorded
|
| Phase 32 trials |
|
Phase 3
|
NCT04631484 |
Nov 2020 → May 2024 |
brain injury |
POLYSAN Scientific & Technological Pharmaceutical Company |
Completed
|
No outcome recorded
|
|
Phase 3
|
NCT02642393 |
Jun 2016 → Jun 2019 |
Parkinson disease |
Michael Alan Schwarzschild |
Completed
|
No outcome recorded
|